IgA肾病残余蛋白尿非免疫抑制剂药物治疗进展  

Progress of non-immunosuppressant therapy for IgA nephropathy with residual proteinuria

作　　者：胡妍琦 李六生[1] HU Yanqi, LI Liusheng(Department of Nephrology, People＇s Hospital of China Three Gorges University, Hubei Province, Yiehang 443000, Chin)

机构地区：[1]三峡大学人民医院肾内科,湖北宜昌443000

出　　处：《中国医药导报》2018年第15期34-37,共4页China Medical Herald

基　　金：湖北省宜昌市科技研究与开发项目(A15301-20)

摘　　要：IgA肾病在全球范围内是导致终末期肾病的主要原因,任何能减少蛋白尿干预措施均有利于延缓IgA肾病进展。目前肾素-血管紧张素系统抑制剂的应用有时并不能使IgA肾病蛋白尿完全缓解,往往需要其他非免疫抑制剂药物治疗,包括鱼油、活性维生素D、舒洛地特、肾素抑制剂、醛固酮受体拮抗剂、他汀类药物等。该文结合国内外文献就IgA肾病残余蛋白尿非免疫抑制剂药物治疗进展作一综述。IgA nephropathy（IgAN） is a common cause of end stage renal disease in the world. Any intervention to reduce proteinuria is helpful to slow the progress of IgAN. At present,sometimes complete remission of IgAN with proteinuria cannot be achieved through the use of renin angiotensin system inhibitor, thus other non-immunosuppressant drugs, including fish oil, active vitamin D, Sulodexide, adrenergic inhibitor, aldosterone receptor blockade, statins and so on are often needed. By analyzing the related literature, this paper reviews the progress of non-immunosuppressant therapy for IgAN with residual proteinuria.

关 键 词：IGA肾病 残余蛋白尿 非免疫抑制剂 药物治疗 

分 类 号：R692.6[医药卫生—泌尿科学]